ABN/ARSN

Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigr	na Pharmaceuticals Limited	15 088 417 403	
We	(the entity) give ASX the following	ng information.	
Info	ormation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	•	x 3D dated 4 October
	al of all shares/units be eptances have been recei		
		Before previous day	Previous day
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	65,734,355	60,000
4	Total consideration paid or payable for the shares/units	\$46,713,090	\$34,458

5

	Before j	previo	us	Previous day
If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.5650
	Lawret			Lowest price paid: \$0.5825
	\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.6122

How many shares/units may still be bought back?

6	If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	
	bought back	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 5 December 2013

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==